Anlotinib enhances the antitumor activity of high-dose irradiation combined with anti-PD-L1 by potentiating the tumor immune microenvironment in murine lung cancer

被引：0
|
作者：
Yuan, M. [1 ]
Zhai, Y. [1 ]
Hui, Z. [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
181P
引用
收藏
页码：S114 / S114
页数：1
相关论文
共 50 条
  • [21] Combination of NK Cells and anti-PD-L1 Ab with ADCC enhances the anti-tumor effects in PD-L1 high cancer cells
    Park, Ji-Eun
    Keam, Bhumsuk
    Park, Ha-ram
    Kim, Soyeon
    Ock, Chan-Young
    Kim, Miso
    Kim, Tae Min
    Kim, Dong-Wan
    Heo, Dae Seog
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [22] Impacts of Combining Anti -PD-1 Immunotherapy and PLDR on the Tumor Immune Microenvironment in a Murine Lung Cancer Model
    Zhang, P.
    Yin, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E419 - E419
  • [23] Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
    Nan, Yanyang
    Bai, Yu
    Hu, Xiaozhi
    Zhou, Kaicheng
    Wu, Tao
    Zhu, An
    Li, Mengyang
    Dou, Zihan
    Cao, Zhonglian
    Zhang, Xumeng
    Xu, Shuwen
    Zhang, Yuanzhen
    Lin, Jun
    Zeng, Xian
    Fan, Jiajun
    Zhang, Xuyao
    Wang, Xuebin
    Ju, Dianwen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (09)
  • [24] Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment
    Kong, Cunqing
    Xu, Banghao
    Qiu, Guanhua
    Wei, Meng
    Zhang, Mengqi
    Bao, Shengxian
    Tang, Jiali
    Li, Lequn
    Liu, JunJie
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2022, 17 : 5391 - 5411
  • [25] The combination of calreticulin-targeting L-ASNase and anti-PD-L1 antibody modulates the tumor immune microenvironment to synergistically enhance the antitumor efficacy of radiotherapy
    Zhang, Ying
    Akhil, Venu
    Seo, Ho Seong
    Park, Hae Ran
    Kim, Soo Hyun
    You, Sung-Hwan
    Liu, Zhipeng
    Kim, So -young
    Sultonova, Rukhsora D.
    Min, Jung-Joon
    Hong, Yeongjin
    THERANOSTICS, 2024, 14 (03): : 1195 - 1211
  • [26] Anti-PD-L1 mAb treatment combined with cisplatin modulates intratumoral immune responses and promotes antitumor effects
    Wakita, Daiko
    Iwai, Toshiki
    Sugimoto, Masamichi
    Harada, Suguru
    Suzuki, Miho
    Yamamoto, Kaname
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [27] GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer
    Huntington, Kelsey E. E.
    Louie, Anna D. D.
    Srinivasan, Praveen R. R.
    Schorl, Christoph
    Lu, Shaolei
    Silverberg, David
    Newhouse, Daniel
    Wu, Zhijin
    Zhou, Lanlan
    Borden, Brittany A. A.
    Giles, Francis J. J.
    Dooner, Mark
    Carneiro, Benedito A. A.
    El-Deiry, Wafik S. S.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (13)
  • [28] Normalization of tumor stroma improves the anti-tumor activity of anti-PD-L1 peptides in pancreatic cancer
    Lin, Chien-Yu
    Cheng, Kun
    CANCER RESEARCH, 2022, 82 (12)
  • [29] Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment
    Li, Huawei
    You, Jia
    Wei, Yuanfeng
    Zheng, Lingnan
    Yang, Ju
    Xu, Jingyi
    Li, Yue
    Li, Zhaojun
    Yang, Xi
    Yi, Cheng
    PHYTOMEDICINE, 2024, 123
  • [30] Characterization of the lung tumor microenvironment upon anti-PD-L1 therapy reveals an ambiguous role for TNF-α
    De Ridder, K.
    Locy, H.
    Piccioni, E.
    Zuazo, M. Ibarra
    Awad, R. M.
    Verhulst, S.
    van Bulck, M.
    De Vlaeminck, Y.
    Lecocq, Q.
    Reijmen, E.
    De Mey, W.
    De Beck, L.
    Ertveldt, T.
    Pintelon, I.
    Timmermans, J-P.
    Escors, D.
    Keyaerts, M.
    Breckpot, K.
    Goyvaerts, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S109 - S109
12345